Patents by Inventor Yoshihisa Arita

Yoshihisa Arita has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240218035
    Abstract: The present invention provides a method for producing active hepatocyte growth factor activator (HGFA) and active hepatocyte growth factor (HGF) without using animal serum. The present invention relates to a method for producing active HGFA without using animal serum. The method is characterized in that it comprises a step of obtaining a culture supernatant comprising pro-HGFA by culturing mammalian cells expressing inactive hepatocyte growth factor activator (pro-HGFA) in a medium without serum, and a step of adjusting the culture supernatant comprising pro-HGFA obtained in the above step to weakly acidic to convert pro-HGFA into active HGFA. The present invention also relates to a method for producing active HGF with HGFA produced by said method.
    Type: Application
    Filed: February 1, 2024
    Publication date: July 4, 2024
    Inventors: Masashi Shimizu, Toshitaka Sato, Yoshihisa Arita
  • Patent number: 11548926
    Abstract: The present invention provides a method for producing active hepatocyte growth factor activator (HGFA) and active hepatocyte growth factor (HGF) without using animal serum. The present invention relates to a method for producing active HGFA without using animal serum. The method is characterized in that it comprises a step of obtaining a culture supernatant comprising pro-HGFA by culturing mammalian cells expressing inactive hepatocyte growth factor activator (pro-HGFA) in a medium without serum, and a step of adjusting the culture supernatant comprising pro-HGFA obtained in the above step to weakly acidic to convert pro-HGFA into active HGFA. The present invention also relates to a method for producing active HGF with HGFA produced by said method.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: January 10, 2023
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Masashi Shimizu, Toshitaka Sato, Yoshihisa Arita
  • Patent number: 11466065
    Abstract: The present invention provides a method for producing active hepatocyte growth factor activator (HGFA) and active hepatocyte growth factor (HGF) without using animal serum. The present invention relates to a method for producing active HGFA without using animal serum. The method is characterized in that it comprises a step of obtaining a culture supernatant comprising pro-HGFA by culturing mammalian cells expressing inactive hepatocyte growth factor activator (pro-HGFA) in a medium without serum, and a step of adjusting the culture supernatant comprising pro-HGFA obtained in the above step to weakly acidic to convert pro-HGFA into active HGFA. The present invention also relates to a method for producing active HGF with HGFA produced by said method.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: October 11, 2022
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Masashi Shimizu, Toshitaka Sato, Yoshihisa Arita
  • Publication number: 20220267393
    Abstract: The present invention provides a method for producing active hepatocyte growth factor activator (HGFA) and active hepatocyte growth factor (HGF) without using animal serum. The present invention relates to a method for producing active HGFA without using animal serum. The method is characterized in that it comprises a step of obtaining a culture supernatant comprising pro-HGFA by culturing mammalian cells expressing inactive hepatocyte growth factor activator (pro-HGFA) in a medium without serum, and a step of adjusting the culture supernatant comprising pro-HGFA obtained in the above step to weakly acidic to convert pro-HGFA into active HGFA. The present invention also relates to a method for producing active HGF with HGFA produced by said method.
    Type: Application
    Filed: May 5, 2022
    Publication date: August 25, 2022
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Masashi Shimizu, Toshitaka Sato, Yoshihisa Arita
  • Patent number: 11325960
    Abstract: The present invention provides a method for producing active hepatocyte growth factor activator (HGFA) and active hepatocyte growth factor (HGF) without using animal serum. The present invention relates to a method for producing active HGFA without using animal serum. The method is characterized in that it comprises a step of obtaining a culture supernatant comprising pro-HGFA by culturing mammalian cells expressing inactive hepatocyte growth factor activator (pro-HGFA) in a medium without serum, and a step of adjusting the culture supernatant comprising pro-HGFA obtained in the above step to weakly acidic to convert pro-HGFA into active HGFA. The present invention also relates to a method for producing active HGF with HGFA produced by said method.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: May 10, 2022
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Masashi Shimizu, Toshitaka Sato, Yoshihisa Arita
  • Patent number: 11168123
    Abstract: The present invention provides a method for producing active hepatocyte growth factor activator (HGFA) and active hepatocyte growth factor (HGF) without using animal serum. The present invention relates to a method for producing active HGFA without using animal serum. The method is characterized in that it comprises a step of obtaining a culture supernatant comprising pro-HGFA by culturing mammalian cells expressing inactive hepatocyte growth factor activator (pro-HGFA) in a medium without serum, and a step of adjusting the culture supernatant comprising pro-HGFA obtained in the above step to weakly acidic to convert pro-HGFA into active HGFA. The present invention also relates to a method for producing active HGF with HGFA produced by said method.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: November 9, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Masashi Shimizu, Toshitaka Sato, Yoshihisa Arita
  • Publication number: 20200341014
    Abstract: The present invention provides a method for evaluating the pharmacological action of HGF that utilizes a PD marker in which fluctuation is recognized by administration of hepatocyte growth factor (HGF) in a broader range of subjects. A method for evaluating the pharmacodynamic action of HGF is provided. The aforementioned evaluation method is characterized in that it comprises a step of measuring the ApoA4 level in a biological sample collected from a test subject who was administered HGF. According to the present invention, a kit for evaluating the pharmacodynamic action of HGF comprising an anti-ApoA4 antibody is further provided.
    Type: Application
    Filed: March 16, 2017
    Publication date: October 29, 2020
    Inventors: Mai Kimura, Sotaro Motoi, Takashi Obara, Katsuhiro Moriya, Hideaki Ogasawara, Yoshihisa Arita, Tetsu Kawano
  • Publication number: 20190062390
    Abstract: The present invention provides a method for producing active hepatocyte growth factor activator (HGFA) and active hepatocyte growth factor (HGF) without using animal serum. The present invention relates to a method for producing active HGFA without using animal serum. The method is characterized in that it comprises a step of obtaining a culture supernatant comprising pro-HGFA by culturing mammalian cells expressing inactive hepatocyte growth factor activator (pro-HGFA) in a medium without serum, and a step of adjusting the culture supernatant comprising pro-HGFA obtained in the above step to weakly acidic to convert pro-HGFA into active HGFA. The present invention also relates to a method for producing active HGF with HGFA produced by said method.
    Type: Application
    Filed: March 15, 2017
    Publication date: February 28, 2019
    Inventors: Masashi Shimizu, Toshitaka Sato, Yoshihisa Arita
  • Publication number: 20090181025
    Abstract: An object of the present invention is to provide a T cell adhesion molecule that is expressed on a dendritic cell. According to the present invention, there is provided a protein comprising the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 or SEQ ID NO: 12.
    Type: Application
    Filed: September 29, 2006
    Publication date: July 16, 2009
    Inventors: Hideaki Ogasawara, Keiko Mizuno, Yoshihisa Arita, Miyuki Nishimura, Toshio Imai